UNSPSC 51261706: Nebivolol hydrochloride

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGS34J7L9I. European Medicines Agency schedules Nebivolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14632MIG. Nebivolol hydrochloride generally arises in the molecular formula C22H25F2NO4.CLH. The term 'nebivolol hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule nebivolol hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, NEBIVOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nebivolol hydrochloride bears US NLM identifiers UMLS ID C0772208 and NCI Concept Code C81656. SMILES: C1CC2C(CC1F)CC[C@@H](O2)[C@@H](CNC[C@H]([C@@H]3CCC4CC(CCC4O3)F)O)O.CL.

UNSPSC 51261706 Nebivolol hydrochloride is a Commodity code that nominally describes a specific beta-blocker pharmaceutical, but the recent state and local opportunities tagged under it diverge substantially from this scope. The Seminole County, Florida IFB60459723LAS solicitation (posted June 30, 2026) procures naloxone and drug deactivation systems rather than nebivolol; the Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026) solicits vendor capabilities for a direct-to-manufacturer prescription program that spans multiple therapeutics classes and contracting models, not a single active ingredient. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope. Issuing bodies in the recent record include a county health department and a state HHS agency, both pursuing broader pharmaceutical procurement strategies—the county through product purchase, the state through exploratory RFI to gather market intelligence on direct-to-manufacturer relationships outside traditional pharmacy benefit manager and group purchasing organization channels.

Geographic activity appears limited to Florida and Texas based on the two recent opportunities. The Seminole County procurement calls for quarterly delivery of approximately 1,900 naloxone units and 800 deactivation systems annually to a Sanford, Florida location, with an initial two-year term and one-year renewal option; the Texas HHS RFI closed April 3, 2026 and represents a preliminary market-assessment phase to inform future RFP design rather than a binding purchase commitment. Neither opportunity directly aligns with nebivolol procurement. Firms pursuing business in pharmaceutical supply to state and local health agencies should monitor this code with caution, as the tagging appears misaligned with its nominal scope.